Filing Details

Accession Number:
0000899243-20-031172
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-16 19:46:54
Reporting Period:
2020-11-12
Accepted Time:
2020-11-16 19:46:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1563577 Galera Therapeutics Inc. GRTX Pharmaceutical Preparations (2834) 461454898
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1774297 F. Joel Sussman C/O Galera Therapeutics, Inc.,
2 W Liberty Blvd #100
Malvern PA 19355
Chief Accounting Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-11-12 10,000 $1.07 10,000 No 4 M Direct
Common Stock Disposition 2020-11-12 10,000 $10.06 0 No 4 S Direct
Common Stock Acquisiton 2020-11-13 3,606 $1.07 3,606 No 4 M Direct
Common Stock Acquisiton 2020-11-13 3,755 $1.14 7,361 No 4 M Direct
Common Stock Acquisiton 2020-11-13 2,639 $2.43 10,000 No 4 M Direct
Common Stock Disposition 2020-11-13 10,000 $10.32 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-11-12 10,000 $0.00 10,000 $1.07
Common Stock Stock Option (Right to Buy) Disposition 2020-11-13 3,606 $0.00 3,606 $1.07
Common Stock Stock Option (Right to Buy) Disposition 2020-11-13 3,755 $0.00 3,755 $1.14
Common Stock Stock Option (Right to Buy) Disposition 2020-11-13 2,639 $0.00 2,639 $2.43
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
3,606 2023-01-22 No 4 M Direct
0 2023-01-22 No 4 M Direct
0 2024-09-16 No 4 M Direct
32,238 2026-03-01 No 4 M Direct
Footnotes
  1. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.00 to $10.25. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.00 to $10.75. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The option has fully vested and is currently exercisable.